New hope for brain cancer: targeted drug combo shows promise

NCT ID NCT07405255

Not yet recruiting Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of zanubrutinib (a targeted drug) plus chemotherapy for people newly diagnosed with central nervous system lymphoma. Nineteen participants will receive the treatment, with an extra drug for those with a specific gene mutation. The goal is to see if the combo can achieve complete remission and keep the disease under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib, rituximab, methotrexate, and possibly selinexor
What this could lead to: If successful, this could offer a new treatment option for central nervous system lymphoma, potentially improving remission rates and long-term control.
What could go wrong: This is a small, early-phase trial with only 19 participants, so results may not apply broadly. The combination therapy may cause significant side effects, and the disease is aggressive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma of the central nervous system primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Ruijin Hospital

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.